COPD trials in China

In China 87 Also abroad 557

87 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Shenzhen, Shijiazhuang, Yangzhou SHI, Zhanjiang
Age
40 years to 80 years
People
402 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07725939 · EU 2026-525523-25-00
Phase 2Taking people
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Where
Baotou, Beijing, Chengdu, Guangzhou, Jiangyin, Jinan, Pingxiang, Shanghai, Shenzhen, Tianjin, Xi'an, Xinxiang
Age
40 years to 75 years
People
606 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07759245 · EU 2026-525480-41-00
Phase 1/2Not yet taking people in China
cfMSC Stem Cell Therapy Targeting COPD
Where
Shenzhen
Age
40 years to 80 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT07477600
No phaseTaking people
Construction and Validation of an Impulse Oscillometry (IOS)-Based Platform for Screening, Diagnosis, and Management of Chronic Airway Diseases
Where
Beijing
Age
18 years to 80 years
People
2,800
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT07910409
Phase 2Taking people
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Where
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hohhot, Jinan, Kunming, Linhai, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Wuhan, Xuzhou, Zhengzhou
Age
40 years and over
People
987 worldwide
Run by
AstraZeneca
See details and how to joinNCT07082738
Phase 3Taking people
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Where
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Foshan, Ganzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Hebei, Hefei, Hohhot, Honghehanizu, Huai'an, Huizhou, Huzhou, Jiangyin, Jiaxing, Jinan, Jingzhou, Jining, Kunming, Lanzhou, Luoyang, Meihekou, Nanchang, Nanjing, Nanning, Nanyang, Panjin, Qingdao, Qingyuan, Qinhuangdao, Qiqihar, Quzhou, Shanghai, Shaoyang, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Ürümqi, Weifang, Wenzhou, Wuhan, Xi'an, Xiangyang, Xinxiang, Xuzhou, Yinchuan, Yiyang, Zhangzhou, Zhengzhou, Zigong, Zunyi
Age
40 years to 80 years
People
942 worldwide
Run by
Sanofi
See details and how to joinNCT07190222 · EU 2024-518213-25-00
No phaseTaking people
A Personalized Mobile Application Providing Temperature-Related Health Risk Warnings and Protective Recommendations for Patients With Chronic Obstructive Pulmonary Disease
Where
Beijing
Age
40 years to 80 years
People
240
Run by
Tiantian Li
See details and how to joinNCT07656142
Phase 2/3Taking people
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
Where
Beijing, Changsha, Chengdu, Chizhou, Chongqing, Fuyang, Guangzhou, Hefei, Hohhot, Huizhou, Jinan, Linhai, Nanchang, Nanjing, Shanghai, Wuhan, Xinxiang, Xuzhou, Yangzhou
Age
35 years to 80 years
People
1,156 worldwide
Run by
Pfizer
See details and how to joinNCT07363694 · EU 2024-518587-12-00
Phase 4Taking people
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Where
Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen
Age
40 years to 85 years
People
218 worldwide
Run by
Sanofi
See details and how to joinNCT07053423
Phase 3Taking people
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Where
Beijing, Changchun, Changsha, Chengdu, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Heifei, Hohhot, Huizhou, Jiaozuo, Jinan, Jinhua, Jining, Kunming, Langfang, Liaocheng, Linhai, Nanchang, Nanning, Ningbo, Pingxiang, Shanghai, Shenyang, Shenzhen, Shihezi, Taiyuan, Taizhou, Tianjin, Ürümqi, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Xiangtan, Xinxiang, Xuzhou, Yangzhou, Yichang, Yinchuan, Zhanjiang, Zhengzhou, Zunyi
Age
40 years to 80 years
People
942 worldwide
Run by
Sanofi
See details and how to joinNCT07190209 · EU 2024-518016-39-00
No phaseTaking people
RESET-COPD Cohort: Real-Time Monitoring and Early Warning in COPD Patients Receiving Home NPPV
Where
Beijing
Age
18 years and over
People
250
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT07701096
No phaseTaking people
Long-term Effects of Endobronchial Valve Implantation on Cardiac Function and Skeletal Muscle Function
Where
Beijing
Age
18 years to 90 years
People
100
Run by
China-Japan Friendship Hospital
See details and how to joinNCT05775588
Phase 3Taking people
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuyang, Guangzhou, Guilin, Haikou, Hangzhou, Hefei, Hohhot, Huizhou, Jiangmen, Jiangsu, Jiangxi, Jinan, Kunming, Lianyungang, Liuzhou, Meizhou, Mianyang, Nanchang, Qingdao, Qingyuan, Qinhuangdao, Shanghai, Suzhou, Taiyuan, Taizhou, Ürümqi, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Yinchuan, Zhanjiang, Zhengzhou, Zigong
Age
40 years to 80 years
People
981 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06959095 · EU 2024-520418-22-00
Phase 3Taking people
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Where
Anning, Anyang, Baotou, Beijing, Changsha, Changzhi, Chengdu, Chifeng, Chizhou, Chongqing, Daqing, Dazhou, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Heze, Hohhot, Huizhou, Jiaozuo, Jinhua, Jining, Kaifeng, Langfang, Lanzhou, Lishui, Liuzhou, Nanchang, Nanjing, Nanyang, Pingxiang, Qingdao, Qingyuan, Ruian, Sanya, Shanghai, Shantou, Shaoxing, Shenyang, Shenzhen, Shihezi, Shijiazhuang, Siping, Suining Shi, Taicang, Taiyuan, Taizhou, Ürümqi, Weifang, Wenzhou, Xiamen, Xi'an, Xiangtan, Xianyang, Xingtai, Xinxiang, Xuzhou, Yangzhou, Yinchuan, Zaozhuang, Zhangzhou, Zhengzhou, Zhuhai, Zhumadian, Zhuzhou, Zigong
Age
40 years to 80 years
People
5,250 worldwide
Run by
AstraZeneca
See details and how to joinNCT06283966 · EU 2023-507407-59-00
No phaseTaking people
Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD
Where
Chengdu
Age
40 years to 85 years
People
189
Run by
Hangzhou Broncus Medical Co., Ltd.
See details and how to joinNCT05799664
Phase 3Taking people
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Where
Baoji, Binzhou, Changchun, Changsha, Changzhi, Chengdu, Chifeng, Chizhou, Chongqing, Dalian, Daqing, Foshan, Guiyang, Haikou, Hefei, Heze, Hohhot, Jiaozuo, Jinhua, Jining, Langfang, Lanzhou, Mianyang, Nanchang, Puyang, Qiqihar, Shanghai, Shangqiu, Shenyang, Shenzhen, Shihezi, Tianjin, Weifang, Wenzhou, Wuxi, Xi'an, Xianyang, Xingtai, Xuzhou, Yangquan, Yangzhou, Yantai, Yichang, Yixing, Yongzhou, Zhangzhou
Age
40 years to 80 years
People
800
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07464587
Phase 3Not yet taking people in China
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Where
Guangzhou
Age
40 years to 75 years
People
102
Run by
Regend Therapeutics
See details and how to joinNCT07828353
No phaseTaking people
IMPACT COPD Cohort (China)
Where
Hebi, Mianyang, Shihezi, Tongliao
Age
40 years to 85 years
People
10,000
Run by
Beijing Chao Yang Hospital
See details and how to joinNCT07382986
No phaseTaking people
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
Where
Shanghai
Age
18 years and over
People
538
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT07823842
Phase 2Taking people
Phase II Study of RC1416 Injection in COPD
Where
Anyang, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Hohhot, Huizhou, Jiangmen, Jiaozuo, Jiujiang, Lianyungang, Liaocheng, Loudi, Mianyang, Nanjing, Nanning, Nanyang, Pingxiang, Qingdao, Qingyuan, Sanmenxia, Shanghai, Shenyang, Suining, Suzhou, Weifang, Wenzhou, Xiamen, Xinxiang, Xuzhou, Yangzhou, Yichang, Yulin, Zaozhuang, Zibo, Zigong, Zunyi
Age
40 years to 85 years
People
180
Run by
Nanjing RegeneCore Biotech Co., Ltd.
See details and how to joinNCT07402551
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
Where
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hengyang, Heze, Hohhot, Huizhou, Jinan, Jinhua, Linhai, Loudi, Nanchang, Nanchong, Nanjing, Nanning, Pingxiang, Qingdao, Qingyuan, Sanya, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suining Shi, Taiyuan, Taizhou, Tianjin, Wenzhou, Wuhan, Xinxiang, Xuzhou, Yangzhou, Yichang, Yinchuan, Zhangzhou
Age
40 years to 80 years
People
990 worldwide
Run by
AstraZeneca
See details and how to joinNCT06883305 · EU 2024-517458-90-00
No phaseNot yet taking people in China
High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
Where
Hangzhou
Age
18 years and over
People
90
Run by
Zhejiang University
See details and how to joinNCT07791979
No phaseNot yet taking people in China
Cross-Regional Unmanned Aircraft Transport of Donor Lungs
Where
Guangzhou
Age
18 years and over
People
25
Run by
The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07790822
No phaseNot yet taking people in China
TCM Cohort for Elderly COPD
Where
Zhengzhou
Age
60 years and over
People
2,386
Run by
Henan University of Traditional Chinese Medicine
See details and how to joinNCT07780682
Phase 2Taking people
A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Where
Shanghai
Age
40 years to 80 years
People
90
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07640451